Free Trial

Repligen (RGEN) Competitors

Repligen logo
$134.00 +4.18 (+3.22%)
Closing price 04:00 PM Eastern
Extended Trading
$134.01 +0.01 (+0.01%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RGEN vs. TECH, A, DHR, TMO, BIIB, INCY, UTHR, NBIX, EXEL, and BMRN

Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector.

Repligen vs. Its Competitors

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Repligen had 2 more articles in the media than Bio-Techne. MarketBeat recorded 10 mentions for Repligen and 8 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.00 beat Repligen's score of 0.80 indicating that Bio-Techne is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Techne
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Repligen
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 3.9% of Bio-Techne shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Bio-Techne has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$1.16B7.36$168.10M$0.8266.35
Repligen$634.44M11.87-$25.51M-$0.45-297.78

Bio-Techne has a net margin of 10.89% compared to Repligen's net margin of -3.93%. Bio-Techne's return on equity of 13.17% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Techne10.89% 13.17% 10.17%
Repligen -3.93%4.53%3.17%

Bio-Techne currently has a consensus price target of $71.36, indicating a potential upside of 31.16%. Repligen has a consensus price target of $170.75, indicating a potential upside of 27.43%. Given Bio-Techne's higher probable upside, equities analysts plainly believe Bio-Techne is more favorable than Repligen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Techne
0 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
Repligen
0 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.69

Summary

Bio-Techne beats Repligen on 12 of the 16 factors compared between the two stocks.

Get Repligen News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGEN vs. The Competition

MetricRepligenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.29B$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-297.788.0519.5820.23
Price / Sales11.87296.11442.27127.79
Price / Cash41.7942.7337.5058.41
Price / Book3.817.748.085.60
Net Income-$25.51M-$54.96M$3.16B$248.43M
7 Day Performance5.21%6.04%3.77%5.15%
1 Month Performance0.85%4.47%3.90%7.62%
1 Year Performance10.79%6.12%34.22%21.56%

Repligen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGEN
Repligen
4.7929 of 5 stars
$134.00
+3.2%
$170.75
+27.4%
+7.4%$7.29B$634.44M-297.781,778Positive News
Analyst Forecast
TECH
Bio-Techne
4.9604 of 5 stars
$51.45
-0.8%
$72.00
+39.9%
-26.2%$8.07B$1.16B62.743,100Positive News
Analyst Forecast
A
Agilent Technologies
4.7098 of 5 stars
$118.06
-0.9%
$140.92
+19.4%
-3.1%$33.54B$6.51B29.1518,100Analyst Forecast
DHR
Danaher
4.8921 of 5 stars
$197.40
-0.7%
$248.61
+25.9%
-16.2%$141.27B$23.82B38.3363,000Positive News
Analyst Forecast
TMO
Thermo Fisher Scientific
4.9577 of 5 stars
$405.83
-0.6%
$604.05
+48.8%
-21.1%$153.20B$42.88B23.80125,000Positive News
Analyst Forecast
BIIB
Biogen
4.9226 of 5 stars
$125.59
-0.4%
$188.48
+50.1%
-41.9%$18.40B$9.68B12.407,605
INCY
Incyte
4.5266 of 5 stars
$68.10
-0.4%
$74.53
+9.4%
+13.2%$13.18B$4.24B212.822,617Insider Trade
UTHR
United Therapeutics
4.9925 of 5 stars
$287.35
+1.1%
$386.15
+34.4%
-6.8%$12.96B$2.88B11.471,305Positive News
Analyst Forecast
NBIX
Neurocrine Biosciences
4.7611 of 5 stars
$125.69
+0.2%
$162.00
+28.9%
-6.8%$12.44B$2.36B42.611,800Trending News
Analyst Forecast
Insider Trade
EXEL
Exelixis
4.5865 of 5 stars
$44.08
+0.9%
$43.56
-1.2%
+99.0%$12.02B$2.17B20.041,147Analyst Forecast
Options Volume
BMRN
BioMarin Pharmaceutical
4.8945 of 5 stars
$54.97
-0.4%
$93.45
+70.0%
-28.1%$10.54B$2.85B20.443,040

Related Companies and Tools


This page (NASDAQ:RGEN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners